BioStock: Increased market potential for Iconovo’s inhalation platforms

Swedish inhalation experts Iconovo offer a faster way to the inhalation market by developing ready-to-use inhalation products, consisting of both the device itself and the dry-powder formulation(s) to go with it. The company’s four inhalation platforms address a huge market worth 14 billion USD in product sales annually. Now, with the recent regulatory approvals of GSK’s Trelegy Ellipta in asthma from the FDA and Novartis’s Enerzair Breezhaler in asthma from the European Commission, Iconovo’s market potential has expanded even further.

Read the full article at biostock.se:

https://www.biostock.se/en/increased-market-potential-for-iconovos-inhalation-platforms/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se